Table 5.
Published trials using third-party VSTs
| VST activator | Virus | Patients | CR or PR | Failure | GVHD | Reference |
|---|---|---|---|---|---|---|
| EBV CTL with prolonged culture* | ||||||
| LCL-induced EBV | EBV | 33 (includes HSCT and SOT) | Fourteen attained CR; 3 had a PR | 16 | None | 71 |
| EBV | 5 | 4 | 1 | None | 10 | |
| EBV | 10 (includes HSCT and SOT) | 8 | 2 | None | 73 | |
| EBV | 4 | 1 | 3 | One with GVHD | 64† | |
| Trivirus CTL with prolonged culture* | ||||||
| AD5/35 pp65-induced CMV/ADV/EBV CTLs | EBV | 9 | 6 | 3 | — | 72 |
| ADV | 18 | 14 | 4 | — | ||
| CMV | 23 | 17 | 6 | — | ||
| TOTAL | 50 | 37 | 13 | Six with grade 1; 2 with grade 2 | ||
| Monovirus VST with short culture‡ | ||||||
| 15-mer peptides spanning the sequence of CMV-pp65 | CMV | 1 | 1 | 0 | None | 27 |
| Trivirus CTL with short culture‡ | ||||||
| Peptide induced CMV/ADV/EBV CTLs | EBV | 2 | 1 | 1 | — | 64† |
| ADV | 1 | 1 | 0 | — | ||
| CMV | 1 | 0 | 1 | — | ||
| TOTAL | 4 | 2 | 2 | — | ||
| γ capture selected cells | ||||||
| γ capture selected from haploidentical donor | ADV | 1 | 1 | 0 | Liver GVHD (no third party cells on biopsy) | 70 |
| Multimer-selected | ||||||
| GLC-peptide separated | EBV | 1 | Attained CR, recurrence 9 mo later; responded to second infusion | 0 | None | 74 |
| HLA-A1–restricted TDLGQNLLY | ADV | 1 | 0 | 1 | None | 54 |
| Peptides from CMV-pp65 | CMV | 4 | 3 | 1 | None | |
| TOTAL | 6 | 4 | 2 | — | ||
*
Prolonged culture = >3 weeks.
†
Only included patients from this review that were not published elsewhere.
‡
Short culture = <3 weeks.
SOT, solid organ transplant.